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Summary We have investigated the relationships between nitrosourea structure and physicochemical
properties and the ability of misonidazole (MISO) to potentiate nitrosourea cytotoxicity in an in vitro model
system. EMT-6/Ro tumour cells were exposed in suspension to each of 9 different nitrosourea anti-tumour
drugs under hypoxic and aerobic culture conditions. Additional cultures were similarly treated with
nitrosoureas in the presence of 1.0mM MISO. Seven of the 9 nitrosoureas did not demonstrate any selective
toxicity toward aerobic or hypoxic cells. In contrast, chlorozotocin (CHLZ) was slightly more toxic toward
hypoxic cells while Bis-OH CyNU more effectively killed aerobic cells. The addition of MISO to the drug
treatment enhanced the effectiveness of all the nitrosoureas under hypoxic conditions, with the exception of
CHLZ which was uninfluenced by MISO.
The magnitude of the MISO dose enhancement factor (DEF, defined as the ratio of drug doses required to
reduce cell survival to S= 10-3 in 4 hours in the absence and presence of 1.0mM MISO) for each
combination was examined as a function of the relative carbamoylating or alkylating activity of the
nitrosourea included in that combination. Such an analysis revealed a significant (P<0.05) positive
correlation between relative carbamoylating potency and DEF. No significant (P>0.20) relationship could be
established for DEF and alkylating activity.
The radiation sensitizer Misonidazole (MISO) has
been shown to enhance the cytotoxicity of many
conventional chemotherapeutic agents (reviewed by
McNally, 1982; Siemann, 1982). However, the
magnitude of chemopotentiation realized when
drugs are combined with MISO is agent-specific,
suggesting that certain inherent properties of
individual drugs are important in determining the
extent of the interaction. Determination of those
properties of anti-tumour drugs which favor an
interaction with MISO would provide valuable
insight into the mechanism(s) of chemopotentiation
and could guide the synthesis of improved chemo-
sensitizing agents.
In the case of nitrosourea chemotherapy agents,
our previous investigations suggest that the extent
of enhancement achieved in MISO-nitrosourea
combinations in vivo might be correlated with the
carbamoylating potential of the nitrosourea used in
the combination (Mulcahy, 1982). However, inter-
pretation of these structure-activity relationships
was complicated by possible differences in bio-
distribution and differential hepatic microsomal
metabolism (Reed, 1981; Weinkam & Lin, 1982;
Lee & Workman, 1983). Furthermore, since the
alkylating and carbamoylating potential of the
nitrosoureas examined were inversely related, (i.e.
an agent with high alkylating activity had a
relatively low carbamoylating activity and vice
versa) it was difficult to clearly discriminate
between the relative significance of these two
activities.
Since the nitrosoureas decay non-enzymatically
generating the same active intermediates in vitro
and in vivo, such a structure-activity relationship
study could be pursued in vitro, thereby minimizing
several of the factors confounding interpretation of
the in vivo experiments. Therefore, to further
evaluate the relationship between carbamoylating or
alkylating activity and MISO chemosensitization,
the potentiation of nitrosourea cytotoxicity by
MISO was investigated in vitro utilizing a select
series of nitrosoureas possessing various alkylating
and carbamoylating potentials.
Materials and methods
Cell line
EMT-6/Ro tumour cells were routinely grown in
BME supplemented with 15% (v/v) foetal and
donor calf serum (1:1) and maintained in an
atmosphere of 97% air/3% CO2 at 37°C. Expo-
nentially growing EMT-6 cells were trypsinized
from monolayers and placed into suspension
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culture for drug exposure. Survival was determined
using a standard plating efficiency assay.
Drugs
The nitrosoureas chosen for these investigations,
their structures and relative alkylating and
carbamoylating activities are listed in Table I.
All nitrosoureas, with the exception of CHLZ,
were initially dissolved in absolute alcohol and
diluted 1:100 upon addition to vials containing
medium and cells. The final concentration of
alcohol (1%) did not significantly influence the
plating efficiency relative to controls. CHLZ was
dissolved in complete BME.
Drug exposure
1-2 x106 EMT-6 tumour cells were suspended in
1Oml of BME in type 1 vials as described by
Whillans & Rauth (1980). For exposures under
aerobic conditions cells were added to BME in the
vials immediately, whereas for hypoxic exposures
the cells were added only after the BME had been
gassed for 3h with a 97% N2/3% CO2 gas mixture
at a flow rate of 75mlmin-1. Prior to their
Table I Structures and chemical activities ofnitrosoureas
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injection at the end of the 3 h gassing period, the
cells were incubated for 15min at a concentration
of - 2 x 107ml- in a Hamilton air-tight syringe
maintained at 37°C. Similar treatment did not
influence the response of EMT-6 cells treated under
aerobic conditions.
To initiate exposure, various concentrations of
the nitrosoureas were injected into each vial,
without interrupting gassing. During the entire
exposure period the vials were continuously purged
with either air/3% CO2 or 97% N2/3% CO2 and a
reduced flow rate of 25mlmin-1. Four hours after
injection, the medium containing drugs and cells
were removed from each vial. The cells were centri-
fuged, washed and resuspended in fresh BME.
For experiments in which cells were exposed to
MISO and the nitrosoureas simultaneously, MISO
was dissolved in complete BME at a concentration
of 1.0mM prior to the initiation of any gassing
sequence, and was present during the gassing phase.
Results
The relative aerobic and hypoxic cytotoxicities of
the various nitrosoureas are displayed in Figure 1.
The majority of the nitrosoureas were equally
effective against EMT-6 cells treated under aerobic
or hypoxic conditions. However, CHLZ and Bis-
OH CyNU, displayed preferential cytotoxicity for
hypoxic and aerobic cultures, respectively.
With the exception of CHLZ the addition of
1.0ml MISO to the incubation medium enhanced
the cytotoxicity of each of the nitrosoureas under
hypoxic conditions. The addition of MISO to Bis-
OH CyNU treatment shifted the dose response
curve to the left such that the combined treatment
was equivalent to aerobic treatment with Bis-OH
CyNU alone, effectively eliminating the protection
afforded by hypoxia. In all cases the aerobic
toxicity of the drugs was not significantly modified
by the addition of 1.0mM MISO. Survival
following 4h treatment with MISO under hypoxic
conditions was 50%. All survival data has been
corrected for the cytotoxicity of MISO alone.
When the Dose Effect Factor (DEF; defined as
the ratio of nitrosourea concentration required to
reduce cell survival to 10-3 under hypoxic
conditions in the absence or presence of 1.0mM
MISO) is plotted as a function of the relative
carbamoylating activity of the individual nitro-
soureas, a significant correlation (P<0.05) between
DEF and carbamoylating potential could be
demonstrated (Figure 2), left hand panel). A similar
analysis as a function of alkylating potential failed
to establish a significant relationship between
enhancement by MISO and alkylation (P>0.2,
Figure 2 right hand panel). Use of DEFs
B.J.C.-C
determined at other isoeffect levels did not
significantly alter the relationships established using
the 10-3 data.
Discussion
The cytotoxicity of the ajiti-neoplastic nitrosoureas
toward tumour cells is thought to be mediated
through the non-enzymatic generation of reactive
daughter products which alkylate DNA, induce
DNA strand cross-linking and thereby interrupt
cellular reproduction (reviewed by Wheeler, 1976;
Kohn et al., 1981). In addition to alkylating species,
the decomposition of the nitrosoureas simul-
taneously gives rise to relatively non-toxic, but
highly reactive (Montgomery et al., 1967)
isocyanates which are capable of carbamoylating
proteins by interacting with -OH, -SH, and -NH2
residues potentially compromising cellular
metabolism, enzyme integrity and repair capacity.
Although virtually all nitrosoureas decompose to
alkylating and carbamoylating intermediates, their
relative alkylating and carbamoylating potential
differ significantly. While alkylation has been
associated with cytotoxicity and mutagenicity
(Wheeler et al., 1974; Bradley et al., 1980),
carbamoylation has been related to DNA repair
inhibition (Kann et al., 1980a) and synergism with
other DNA damaging agents such as ionizing
radiation (Kann et al., 1980b) and conventional
alkylating agents (Schabel, 1976).
Initial in vivo studies evaluating the effectiveness
of combining MISO with BCNU (Mulcahy et al.,
1981), CCNU (Siemann, 1981) and CHLZ
(Mulcahy et al., 1982) indicated that the magnitude
of the resulting chemopotentiation was nitrosourea
dependent, in spite of the drugs structural
similarities (Table I). Since these agents differed
significantly with respect to alkylating and
carbamoylating properties we investigated the
relationship between these chemical properties and
each of the nitrosourea's interaction with MISO.
These studies, as well as subsequent in vivo investi-
gations, suggested that carbamoylation, rather than
alkylation, was directly related to the extent of
MISO chemosensitization (Mulcahy, 1982).
Additional support for such a hypothesis was
provided by further work in the KHT tumour
system indicating that the repair of potentially
lethal damage (PLD) occurring after MISO-nitro-
sourea treatment was likewise inhibited in direct
proportion to relative carbamoylating activity.
Although highly suggestive, interpretation of the
in vivo results may have been complicated by
several factors including differences in drug
distribution, hepatic metabolism and lipid-
solubility. Furthermore, owing to the inverse310 R.T. MULCAHY et al.
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Figure 1 Dose response curves for EMT-6/Ro cells treated with various nitrosoureas in vitro for 4h under
aerobic (open symbols) or hypoxic (closed symbols) conditions and for EMT-6/Ro cells similarly treated in
hypoxia with the nitrosoureas and 1.0mM MISO (O, Ol). Different symbols represent different
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Figure 2 A significant correlation (P<0.05) is observed between DEF at S= 10-3 and relative
carbamoylating activity (left panel); while no correlation (P> 0.2) is seen between DEF and alkylating activity
(right panel). The numbers adjacent to each data point refer to the nitrosoureas in Table I.
relationship between the alkylating and carbamoy-
lating potential of the nitrosoureas used in these
earlier studies, it has been difficult to conclusively
determine whether MISO chemopotentiation was
related to high carbamoylating activity or low
alkylating activity. We chose therefore to further
evaluate the structure-activity relationship in vitro
in an attempt to reduce or eliminate the influences
of some of the complicating factors encountered in
vivo. Such studies take advantage of the fact that
a broad spectrum of alkylating and carbamoylating
activities can be generated non-enzymatically from
various nitrosoureas in vitro as well as in vivo. In
addition, the in vitro studies were expanded to
include nitrosoureas with similar alkylating
activities but differing carbamoylating activities,
and vice versa, in order to facilitate discrimination
between the relative significance of high carbamoy-
lation or low alkylation.
As can be seen in Figure 2, MISO potentiates the
hypoxic activity of the nitrosoureas in proportion
to their relative carbamoylating potential;
confirming our previous observations with KHT
tumours in vivo. An inverse relationship between
alkylating activity and chemopotentiation is not
supported by the current findings. These studies
identify a chemical property linked to MISO-nitro-
sourea interaction in vitro, making it possible to
evaluate currently proposed mechanisms of
potentiation in light of this new information.
Pharmacokinetic alteration secondary to MISO
inhibition of hepatic microsomal drug metabolism
was identified as a possible mechanism in early
chemosensitization reports (Tannock, 1980;
Mulcahy et al., 1981), and is considered the major
mechanism by many. Such a hypothesis is strongly
supported by extensive CCNU pharmacokinetic
investigations recently reported by Lee & Workman
(1983). These authors further suggest that
pharmacokinetic alterations may provide an
alternative explanation to our initial in vivo
correlation between carbamoylation and chemo-
potentiation since carbamoylating potential and
partition coefficient, (a property which may
determine the extent of hepatic metabolism) were
proportional for each of the nitrosoureas included
in our 5 drug series. While pharmacokinetic
changes are likely to be involved in nitrosourea
chemosensitization in vivo to a greater or lesser
extent, it is difficult to reconcile all the available
chemosensitization data in light of this mechanism
alone. Especially difficult to explain on this basis is
in vitro data which clearly establish that MISO can
enhance drug cytotoxicity without modification of
drug decay (Tannock & Guttman, 1982; Mulcahy
& Dembs, 1983). It is unlikely, for example, that
the relationship observed in the current in vitro
studies is the result of modified nitrosourea
decomposition because the decay of BCNU, CCNU
and CHLZ in vitro is unaltered by MISO (Tannock
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& Guttman, 1982; Mulcahy & Dembs, 1983; Lee &
Workman, 1983). The association between PLD
repair inhibition in KHT tumour treated with
MISO-nitrosourea combinations and relative
carbamoylating potential (Siemann & Mulcahy,
1982) is likewise difficult to explain on a pharmaco-
kinetic basis, suggesting that the enhancement of
nitrosourea cytotoxicity by MISO involves other
interactions in addition to any pharmacokinetic
alterations.
Considering these later data and the reported
repair-inhibiting capacity of carbamoylating nitro-
soureas it would seem logical to propose that PLD
repair-inhibition is somehow involved in MISO
chemosensitization of nitrosourea toxicity.
Although evidence exists to support this possibility
for nitrosoureas as well as other drugs in vivo
(reviewed by McNally, 1982; Siemann, 1982), this
particular phenomenon is unlikely to contribute to
the correlation reported here since all attempts to
demonstrate PLD repair in EMT-6 cells after nitro-
sourea treatment in vitro have failed (Twentyman,
1978; Mulcahy, unpublished).
A plausible alternative explanation for our in
vitro results is based on the observed selective
inhibitory effect of nitrosoureas on the enzyme
glutathione reductase (Babson & Reed, 1978), and
intercellular glutathione (GSH) levels. This
inhibition, which is proportional to carbamoylating
potential (Babson & Reed, 1978) prevents the
recycling of glutathione from its oxidized form
(GSSG) back to reduced GSH. The depletion of
non-protein sulfhydryls (primarily GSH) associated
with MISO treatment under hypoxia has already
been identified as an integral part of MISO's cyto-
toxicity and chemosensitizing ability in vitro
(reviewed by Brown, 1982; Roizin-Towle et al.,
1982). According to our hypothesis the chemo-
potentiation observed in our in vitro studies is
linked to thiol depletion by MISO and the
additional effects of carbamoylation on glutathione
reductase and consequently GSH. The end result
would be to augment the GSH depletion associated
with the hypoxic reduction of MISO and its meta-
bolites while preventing recycling of GSSG
(Mulcahy & Dembs, 1983). As previously suggested
(Mulcahy & Dembs, 1983), this might also explain
why it is possible to sensitize these agents in vitro
with doses of MISO (0.25-1.0mM for 4h)
considered to be too low to adequately reduce
thiols concentrations to levels compatible with
chemosensitization.
It should be noted that the carbamoylating
potential used as reference values in this report are
based on the carbamoylation of L-lysine in vitro.
These values, determined by Wheeler and
colleagues at the Southern Research Institute,
Birmingham, Alabama, USA (Wheeler et al., 1974;
Wheeler, 1976) are the standard values utilized in
virtually all research involving nitrosoureas.
However, there is evidence that certain nitrosoureas
which lack the ability to carbamoylate L-lysine in
vitro, such as ACNU, are potent carbamoylators of
other compounds, such as glutathione reductase
(Babson & Reed, 1978). It is therefore premature to
exclude the possibility that nitrosoureas showing
limited carbamoylating potential in the L-lysine
system may have selective-activity against other test
compounds in vitro or in vivo. With this reservation
in mind we have begun to re-standardize the nitro-
soureas employed in our studies for their ability to
carbamoylate glutathione reductase in vitro and in
vivo. It seems unlikely that this re-standardization
will adversely affect the correlation reported here
since a similar conclusion is obtained if our DEF
values are correlated with the specific carbamoy-
lation of glutathione reductase reported by Babson
& Reed (1978) for several of the nitrosoureas used
in our investigations.
Based on our experience with the chemosensi-
tization of nitrosoureas, we elected to synthesize
novel nitro-compounds possessing a leaving group
which would liberate an organic isocyanate; similar
to the carbamoylating portion generated by the
decomposition of the nitrosoureas. Preliminary
evaluation of the first few such agents indicate that
the addition of a carbamoylating moiety can
produce compounds with enhanced chemosensi-
tizing, radiosensitizing and hypoxic cytotoxicity
properties as compared to similar structures devoid
of an isocyanate precursor.
In conclusion, these studies have demonstrated a
correlation between carbamoylation and chemo-
sensitization of a variety of nitrosoureas by MISO
in vitro, in agreement with previous studies in the
KHT tumour system. We hypothesize that the
mechanism of this in vitro effect is related to
alterations in the GSH cycle, perhaps secondary to
carbamoylation of key enzymes, notably
glutathione reductase. Finally, the information
gained has been applied to the synthesis of
potentially improved modifiers of chemotherapy
and radiation responses.
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